AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT04425564 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Blood samples for pharmacological studies
Study NCT04425564 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Blood samples for pharmacological studies
Study NCT01343550 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: creativity group
Description: This is a creativity group intervention. There will be 4 groups. Each group has one session per week. Each session is a duration of two hours.
Study NCT03330379 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Tracoe Smart CuffmanagerTM
Description: In patients randomly assigned to the continuous adjustment strategy, in addition to standard care, the Tracoe Smart CuffmanagerTM will be connected to the tracheal cuff. Within the 2 days following the inclusion, all the intermittent Pcuff measurements will be collected as well as the incidence of Pcuff manual adjustments
Study NCT02820779 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: WILLIS
Description: WILLIS® intracranial stent graft system is composed of the stent, delivery system, cobalt-based alloy stent and PTFE graft. It can effectively shunt the blood flow and keep it off of the aneurysm wall.
Study NCT02114593 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Parent support program
Description: Parent support program
Study NCT00908479 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Leg Exercise Program
Description: Participants will engage in an extra 45-60 minutes per day of self-managed lower extremity homework exercises focused on improving strength, balance and walking ability.
Study NCT00908479 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Leg Management group
Description: Therapist provides educational information about leg pain, recovery, bone density, and fall risk.
Study NCT01748929 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Albendazole
Study NCT01748929 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Study NCT00709969 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Artemether-lumefantrine
Description: 20mg artemether and 120 mg lumefantrine, tablet, dose based on body weight, 3 days treatment 5 - \< 10kg (BWG 1) = 6 doses of 1 tablet / 10 - \< 15kg (BWG 2) = 6 doses of 1 tablet / 15 - ≤ 25kg (BWG 3) = 6 doses of 2 tablets
Study NCT00674986 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Accu-Chek 360° View Blood Glucose Analysis Tool
Study NCT00674986 — intervention group
Intervention type: DEVICE
Group type: OTHER
Intervention: Accu-Chek Aviva Glucose Meter
Study NCT00674986 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Accu-Chek Aviva Glucose Meter
Study NCT01461668 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Retapamulin
Description: Two times a day for 5 days
Study NCT01461668 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Two times a day for 5 days
Study NCT02732418 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Depo-Provera CI
Description: The active ingredient in Depo-Provera is Medroxyprogesterone acetate (MPA)
Study NCT02732418 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Depo-subQ 104
Description: The active ingredient in Depo-Provera is Medroxyprogesterone acetate (MPA). Depo-subQ provera 104® (medroxyprogesterone acetate injectable suspension, 104 mg/0.65mL) for subcutaneous injection
Study NCT02242474 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Anti-TNF suspended perioperatively
Study NCT02242474 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Anti-TNFα continued perioperatively
Study NCT01691066 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Infant Toddler Years PRT
Study NCT00829257 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: HFA-BDP
Description: HFA-BDP (Qvar) 100ug 2puff b.i.d
Study NCT00829257 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Fluticasone
Description: Fluticasone propionate Accuhaler 250ug b.i.d.
Study NCT00829257 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Seretide
Description: Fluticasone/Salmeterol (Seretide) 500/50ug, 1 puff b.i.d
Study NCT00829257 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Seretide
Description: Fluticasone/Salmeterol (Seretide) 500/50ug, 1 puff b.i.d
Study NCT04797338 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Synarel, 0.2 Mg/Inh Nasal Spray
Description: Intranasal treatment with Nafarelin inhaler: 200 micrograms twice daily (a total of 400 micrograms/d; Synarel, Pfizer) on the evening after oocyte retrieval, which will be continued up to the bHCG blood test, 12 days post embryo transfer. In cases with positive serum bHCG results, the treatment will be stopped.
Study NCT04797338 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Estrofem
Description: A combination of oral estrogen (Estrofem or Progynova 4 mg twice daily), vaginal progesterone (vaginal Utrogestan 200mg or Endometrin 100 mg three times daily) and intramuscular injection of Hydroxyprogesterone Caproate 250 mg once every five days. The treatment will start at the day of the oocyte retrieval up to the bHCG blood test, 12 days post embryo transfer. In cases with positive serum bHCG results, the treatment will be continued up to 9+0 weeks of pregnancy.
Study NCT04797338 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Utrogestan
Description: A combination of oral estrogen (Estrofem or Progynova 4 mg twice daily), vaginal progesterone (vaginal Utrogestan 200mg or Endometrin 100 mg three times daily) and intramuscular injection of Hydroxyprogesterone Caproate 250 mg once every five days. The treatment will start at the day of the oocyte retrieval up to the bHCG blood test, 12 days post embryo transfer. In cases with positive serum bHCG results, the treatment will be continued up to 9+0 weeks of pregnancy.
Study NCT04797338 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Hydroxyprogesterone Caproate
Description: A combination of oral estrogen (Estrofem or Progynova 4 mg twice daily), vaginal progesterone (vaginal Utrogestan 200mg or Endometrin 100 mg three times daily) and intramuscular injection of Hydroxyprogesterone Caproate 250 mg once every five days. The treatment will start at the day of the oocyte retrieval up to the bHCG blood test, 12 days post embryo transfer. In cases with positive serum bHCG results, the treatment will be continued up to 9+0 weeks of pregnancy.
Study NCT00342316 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Reduced Intensity Conditioning Stem Cell Transplantation
Description: One of the following conditioning regimens:~1. Busulphan (orally or IV), fludarabine~2. Fludarabine, carmustine, melfalan~3. Cyclophosphamide, fludarabine
Study NCT02701218 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Canalith repositioning procedure
Description: Canalith repositioning procedure; single or multiple cycles
Study NCT02263651 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Quilting suture without drainage
Description: In an attempt to obliterate the dead space, the skin flaps are sutured to the underlying pectoralis major with multiple parallel rows of 0/0 vicryl (or equivalent). Running sutures at periodic intervals (\<2cm) are placed from the skin flaps to the underlying muscle. Minor dimpling is considered acceptable and is expected to resolve. If severe dimpling is observed, stitches are removed and replaced.~Efficiency of quilting suture relies on a rigorous repartition of the sutures with a special attention taken to the obliteration of the largest potential dead spaces and the empty axillary apex.~The skin edges are sutured as stated before for the control group. Closed suction will not be used for draining the pectoral area.
Study NCT02263651 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Conventional closure with drainage
Description: The skin flaps are not fixed subcutaneously but sutured at the edges, a closed suction drain is inserted under the flaps in the dead space created by the dissection at the pectoral area. The drain is stitched to the skin.~The skin is closed in two layers with absorbable sutures, a deep layer of 2.0 or 3.0 vicryl sutures or equivalent, and a subcuticular closure with absorbable 3.0 or 4.0 Monocryl sutures or equivalent.
Study NCT04139070 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bleomycin
Description: Electroporation in combination with systemically administered bleomycin
Study NCT05446987 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Position change and back massage
Description: Changing the patient's position every two hours as follows in the same order: supine position with a head angle of 15°, semi-fowler position with a head angle of 30°, lateral right or left position with a head angle of 15°. Also, the researcher applied a simple stroke of lower back massage for 5 minutes every 2 hours
Study NCT05446987 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Early ambulation
Description: The patient ambulated after 3 hours of complete bed rest in the supine position with a zero head of bed elevation angle
Study NCT04567472 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Helping Ease Anxiety and Depression following Stroke
Description: HEADS: UP online is a group-based mindfulness course with an accompanying text-based manual. HEADS: UP comprises 9 x 2.5 hour mindfulness sessions, which incorporate a 30-minute break. A 6-hour silent retreat is offered in week 7. A follow-up session will be offered 6 - 8 weeks after the end of the course. Course materials include accessible information packs delivered weekly, electronically, and CD/audio resources to complement the sessions. The accompanying text-based manual will be delivered 'up front' (hard copy and electronic). A summary email and reminder of personal practice will be sent to participants after each session, including links to audio resources complementing class-based sessions. Signposting to other resources and media, including sites with downloadable voice files e.g. Mindfulness Scotland will be included.
Study NCT04455035 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Comparator: Retrospective Group(Control)
Description: The control group for this study will be obtained from a retrospective chart review of electronic health records of patients with incomplete cleft lip who underwent surgery without any presurgical interventions.
Study NCT04455035 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Prospective Group
Description: The study population for the prospective aspect will include recruited newborns with untreated unilateral incomplete cleft lip.~DynaCleft® + Nasal Elevator therapy will be discussed with parent(s) as a presurgical orthopedic option while awaiting primary cleft lip surgical repair that typically occurs between the ages of 3 to 6 months.Study duration will be up to three months of presurgical intervention.Photographs are to be taken at initial visit prior to presurgical intervention and later at completion of the DynaCleft® therapy immediately prior to lip surgery. Angles to be pictured are to include the standard anterior-posterior, profile, and worms-eye view.~Linear measurements will be obtained with a ruler and registered in millimeters. A goniometer will be used to measure angles.
Study NCT04636255 — intervention group
Intervention type: PROCEDURE
Group type: SHAM_COMPARATOR
Intervention: Physical Characteristics
Description: Body Weight, Height
Study NCT04636255 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Physical Characteristics
Description: Body Weight, Height
Study NCT04636255 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: SHAM_COMPARATOR
Intervention: Assessment of Heart rate variability
Description: Holter 24h
Study NCT04636255 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Assessment of Heart rate variability
Description: Holter 24h
Study NCT04636255 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: SHAM_COMPARATOR
Intervention: Blood Pressure and Cardiac Autonomic Control
Description: Non-invasive photoplethysmography (Finometer® PRO) monitored by the electrocardiogram and respiratory frequency by a piezoelectric chest strap.
Study NCT04636255 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Blood Pressure and Cardiac Autonomic Control
Description: Non-invasive photoplethysmography (Finometer® PRO) monitored by the electrocardiogram and respiratory frequency by a piezoelectric chest strap.
Study NCT04636255 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: SHAM_COMPARATOR
Intervention: Evaluation of Baroreflex Control
Description: The magnitude and latency of the baroreflex control of the heart rate will be assessed by bivariate analysis using the autoregressive method.
Study NCT04636255 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Evaluation of Baroreflex Control
Description: The magnitude and latency of the baroreflex control of the heart rate will be assessed by bivariate analysis using the autoregressive method.
Study NCT04636255 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: SHAM_COMPARATOR
Intervention: Cardiac Function and Structure
Description: Echocardiogram
Study NCT04636255 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Cardiac Function and Structure
Description: Echocardiogram
Study NCT04636255 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: SHAM_COMPARATOR
Intervention: Assessment of Coronary Anatomy and Calcium Score
Description: Angiotomography
Study NCT04636255 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Assessment of Coronary Anatomy and Calcium Score
Description: Angiotomography
Study NCT04636255 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: SHAM_COMPARATOR
Intervention: Blood Assessments
Description: Serum and Plasma will be extracted by centrifugation. NT-pro BNP (Roche™) and c-TnI (imunoassay Elecys 2010).
Study NCT04636255 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Blood Assessments
Description: Serum and Plasma will be extracted by centrifugation. NT-pro BNP (Roche™) and c-TnI (imunoassay Elecys 2010).
Study NCT03084107 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Questionnaire
Description: The elderly participated in the application of smart devices and requested to complete technology acceptance model (TAM) questionnaires for these devices.
Study NCT02767466 — intervention group
Intervention type: PROCEDURE
Intervention: Physical therapy and robotic assisted gait training
Study NCT05101889 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Oral Impact®
Description: 3 ready-to-drink bottles/day
Study NCT05101889 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Oral Impact®
Description: 3 ready-to-drink bottles/day
Study NCT03618160 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: JNJ-64565111
Description: Participants in Cohorts 1 to 3 will receive a single SC low, medium, and high dose of JNJ-64565111 respectively on Day 1, participants in Cohorts 4 to 6 will receive weekly multiple SC low, high and medium dose of JNJ-64565111 respectively on Days 1, 8, 15, and 22, under fasted conditions. Participants in Cohort 7 will receive a single SC medium dose of JNJ-64565111 on Day 1, under fasted conditions.
Study NCT03618160 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Participants will receive SC injection of matching placebo on Day 1 in all cohorts of Part 1 and on Days 1, 8, 15, and 22 in Part 2 under fasted conditions.
Study NCT02801513 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Brief Mindfulness Training
Description: Brief mindfulness training comprising of three weekly individual sessions and daily guided meditation home practice
Study NCT02801513 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Resting Control Training
Description: Brief resting control training comprising of three weekly individual sessions and daily home practice consisting of resting periods
Study NCT03726047 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Exercise
Description: Subjects will complete 5 minutes of exercise on an ergometer to examine the effects of exercise on retention of a newly learned walking pattern.
Study NCT04636255 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: SHAM_COMPARATOR
Intervention: Physical Capacity
Description: Cardiopulmonary Exercise Test.
Study NCT04636255 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Physical Capacity
Description: Cardiopulmonary Exercise Test.
Study NCT04636255 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Physical Training
Description: Aerobic exercise: 48 sessions of 60 minutes: 5 minutes of warm-up, 40 minutes of exercise. Resistance exercise: 10 minutes of exercise and 5 minutes of recovery.
Study NCT03321968 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Quadrivalent VLP Influenza Vaccine
Description: Single dose of 30 µg/strain Quadrivalent VLP Influenza Vaccine
Study NCT02138487 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: liberal postoperative activity
Description: Women will be given specific instructions regarding postoperative activities and will not have any limitations regarding activity.
Study NCT02138487 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Restricted postoperative activity
Description: Women in this group will be given instructions regarding postoperative activity and will need to abstain from heavy lifting, running, aerobics for 3 months.
Study NCT02337608 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GLPG1205
Description: GLPG1205 daily dosing in the morning for 12 weeks
Study NCT02337608 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: placebo daily dosing in the morning daily for 12 weeks
Study NCT02804594 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: N-acetyl cysteine
Description: 1250 mg of N- acetyl cysteine taken three times daily
Study NCT02804594 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: placebo taken three times daily
Study NCT03425201 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Niraparib plus Cabozantinib
Description: Non-randomized trial will comprise 2 stages. A dose escalation phase will characterize the safety, tolerability, DLTs and MTD, of oral niraparib plus cabozantinib in patients with urothelial or renal cell carcinoma. Subsequently, the phase II will further evaluate the safety and antitumor activity of this combination in patients with urothelial carcinoma.
Study NCT03226808 — intervention group
Intervention type: DEVICE
Group type: OTHER
Intervention: Vivacit-E Liner
Description: All subjects enrolled will receive the Vivacit-E liner.
Study NCT03467542 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: PHIL® Liquid Embolic System
Description: The PHIL Embolic System is indicated in the treatment of dural arteriovenous fistulas (DAVF)
Study NCT02733848 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Creon
Description: Creon is a porcine derived pancreatic enzyme supplement that comes in in fixed dose combinations of lipase, protease, and amylase, respectively. Dosing is based on lipase per kilograms per meal (i.e. lipase units/kg/meal). Subjects will be started at a dose of 500 units of lipase/kg/meal and snacks at week 4 and continued until week 8. A follow-up visit at week 6 will assess patient for tolerance to Creon and need for dosage adjustment.~Formulations come in different fixed dose combinations as follows:~Creon: Lipase 3000 USP units, protease 9500 USP units, and amylase 15,000 USP units~Creon: Lipase 6000 USP units, protease 19,000 USP units, and amylase 30,000 USP units~Creon: Lipase 12,000 USP units, protease 38,000 USP units, and amylase 60,000 USP units~Creon: Lipase 24,000 USP units, protease 76,000 USP units, and amylase 120,000 USP units~Creon: Lipase 36,000 USP units, protease 114,000 USP units, and amylase 180,000 USP units
Study NCT02733848 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Diet
Description: A registered dietician will meet with the subject and take a thorough review of the patient's dietary history. The subject will then be counseled on a lower carbohydrate and higher protein diet. This diet will be continued for the entire 12 week of the study. The registered dietician will reinforce dietary recommendations by phone on week 2, 4 and 8, respectively.
Study NCT01830595 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Recombinant Lactoferrin
Study NCT01830595 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Study NCT02733848 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo will be given to the patient in single blind fashion with the subject unaware but PI aware of study drug assignment from week 8-12. Placebo tablets will be given with meals and snacks similar to CREON to maintain patient blinding to study drug assignment. A follow-up visit on week 10 to review patient tolerance, side effects and possible drug adjustment.
Study NCT01811641 — intervention group
Intervention type: OTHER
Intervention: season, dietary intake
Study NCT02014311 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: CTA+CTP guided treatment strategy
Description: CTA+CTP guided treatment strategy
Study NCT02014311 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: CTA guided treatment strategy
Description: CTA guided treatment strategy
Study NCT01172925 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tiotropium
Description: Inhaler
Study NCT01172925 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Inhaler